Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04
The Journal of Dermatology · 2024
DOI: 10.1111/1346-8138.17082 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Ryo Amagai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: HLA-DRB1 Chains, Melanoma, Uveomeningoencephalitic Syndrome, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
The combination of BRAF kinase inhibitors (BRAFis) and MEK kinase inhibitors (MEKis) is one of the most promising chemotherapy regimens in the treatment of BRAF‐mutant melanoma. Although BRAFi plus MEKi combined therapy is widely used for the treatment of BRAF V600 ‐mutated melanoma, the incidence of uveitis caused by BRAFi plus MEKi is limited. In this report, we described five cases (two men and three women) of Vogt‐Koyanagi‐Harada (VKH) disease‐like uveitis in melanoma patients who received BRAFi plus MEKi combined therapy. Of note, all the patients had the HLA‐DRB1*04 haplotype, which is frequently detected in VKH‐like non‐infectious uveitis. On the other hand, among BRAFi plus MEKi‐treated patients who did not develop VKH disease‐like uveitis, only one of five (20%) patients had the HLA‐DRB1*04 haplotype. Collectively, BRAFi/MEKi might induce severe VKH disease‐like uveitis in melanoma patients with the HLA‐DRB1*04 haplotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.
ORCID-Profile: Ryo Amagai, Taku Fujimura
Zitieren
APA
Amagai, R., Fujimura, T., Yamazaki, E., Takahashi, M., Tamabuchi, E., Kambayashi, Y., Hashimoto, A., Hashimoto, K., & Asano, Y. (2024). Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17082
Vancouver
Amagai R, Fujimura T, Yamazaki E, Takahashi M, Tamabuchi E, Kambayashi Y, et al. Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17082
BibTeX
@article{Amagai2024,
author = {Amagai, Ryo and Fujimura, Taku and Yamazaki, Emi and Takahashi, Manami and Tamabuchi, Erika and Kambayashi, Yumi and Hashimoto, Akira and Hashimoto, Kazuki and Asano, Yoshihide},
title = {Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04},
journal = {The Journal of Dermatology},
year = {2024},
doi = {10.1111/1346-8138.17082}
}
EUVIMED